Zacks Research Issues Pessimistic Outlook for PBH Earnings

Key Points

• Zacks Research has downgraded Prestige Consumer Healthcare's Q2 2026 earnings estimate to $0.98 per share, down from a previous estimate of $0.99, and has assigned a "Strong Sell" rating on the stock.
• In its latest earnings report, Prestige Consumer Healthcare reported $0.95 EPS, missing analyst expectations by $0.06, and faced a 6.6% decline in quarterly revenue compared to the previous year.
• Four analysts currently rate Prestige Consumer Healthcare with a Buy rating, while two have issued a Hold rating, and one has given a Sell rating, resulting in an average rating of "Hold" with a price target of $94.80.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at Zacks Research lowered their Q2 2026 earnings estimates for Prestige Consumer Healthcare in a report issued on Thursday, October 16th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.98 for the quarter, down from their prior forecast of $0.99. Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q2 2027 earnings at $1.17 EPS, Q3 2027 earnings at $1.13 EPS and Q2 2028 earnings at $1.30 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm's quarterly revenue was down 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

A number of other research analysts have also recently issued reports on PBH. Sidoti upgraded shares of Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a report on Wednesday, September 24th. Weiss Ratings restated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Hold" and an average price target of $94.80.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of NYSE PBH opened at $62.08 on Monday. The stock has a market capitalization of $3.05 billion, a P/E ratio of 14.57, a P/E/G ratio of 1.96 and a beta of 0.44. The company has a 50-day moving average price of $64.31 and a 200-day moving average price of $75.24. Prestige Consumer Healthcare has a 1 year low of $60.15 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after acquiring an additional 496 shares during the last quarter. KBC Group NV boosted its stake in Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after acquiring an additional 151 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Prestige Consumer Healthcare by 8.6% in the first quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock valued at $513,000 after acquiring an additional 475 shares during the last quarter. Intech Investment Management LLC boosted its stake in Prestige Consumer Healthcare by 18.9% in the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company's stock valued at $2,348,000 after acquiring an additional 4,343 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in Prestige Consumer Healthcare by 354.0% in the first quarter. XTX Topco Ltd now owns 22,778 shares of the company's stock valued at $1,958,000 after acquiring an additional 17,761 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.